1Department of Dermatology, Venereology and Leprosy, North DMC Medical College and Hindu Rao Hospital, Delhi-110007
2Chief Medical Officer, Department of Dermatology, Venereology and Leprosy, North DMC Medical College and Hindu Rao Hospital, Delhi-110007
3Junior Resident, Department of Dermatology, Venereology and Leprosy, North DMC Medical College and Hindu Rao Hospital, Delhi-110007
4Junior Resident, Department of Dermatology, Venereology and Leprosy, North DMC Medical College and Hindu Rao Hospital, Delhi-07
5Professor, Department of Community Medicine, North DMC Medical College and Hindu Rao Hospital, Delhi
6Department of Community and Family Medicine, AIIMS. Bibingar, Hyderabad,Telangana,India-508126
چکیده
Tranexamic acid (TXA) is an antifibrinolytic agent commonly used for the treatment or prevention of bleeding. Indications for TXA are diverse, including heavy menstrual bleeding, trauma, postpartum hemorrhage, traumatic brain injury, and surgical site bleeding. Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with the virus will experience mild to moderate respiratory illness and recover without requiring special treatment. However, some will become seriously ill and require medical attention. Older people and those with underlying medical conditions like cardiovascular disease, diabetes, chronic respiratory disease, or cancer are more likely to develop serious illness. Anyone can get sick with COVID-19 and become seriously ill or die at any age. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2 or COVID-19) originated in Wuhan, China has spread at an alarming pace throughout the world and declared as a pandemic by the World Health Organization. The air droplet spread of SARS-CoV2 which is potentially fatal is of great global health concern. Various drugs and treatment modalities have been tried to date but none has been found to be definitive. Tranexamic acid commonly used in pigmentary disorders in Dermatology due to its ability to reduce the melanocyte tyrosinase activity also possesses anti-fibrinolytic and anti-inflammatory properties which have been observed to suppress the cytokine storm and modulate coagulopathy in patients suffering from COVID19. Tranexamic acid when administered early has been effective in decreasing the severity of symptoms in patients of COVID-19 but on the contrary, has also been associated with life-threatening thrombosis if given as a single drug.
World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19-11. Geneva: 2020.
Okamoto S, Okamoto U. Amino‐methyl‐cyclohexane‐carboxylic acid: AMCHA. A new potent inhibitor of fibrinolysis. Keio J Med. 1962;11:105‐115.
Binz S, McCollester J, Thomas S, Mil ler J, Pohlman T, Waxman D, et al. CRASH‑2 study of tranexamic acid to treat bleeding in trauma patients: A controversy fueled by science and social media. J Blood Transfus. 2015;2015:874920.
Dunn CJ, Goa KL. Tranexamic acid: A review of its use in surgery and other indications. Drugs. 1999;57:1005‑32.
Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. J Res Med Sci. 2014;19:753‑7.
Ji HL, Zhao R, Matalon S, Matthay MA. Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev. 2020;100(3):1065–1075.
McCormack PL. Tranexamic acid: a review of its use in the treatment of hyper fibrinolysis. Drugs. 2012;72(5):585–617.
Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol. 1981;20(1):65-72.
Nijo T. Treatment of melasma with tranexamic acid. Clin Res. 1979;13:3129-31.
Takashima A, Yasuda S, Mizuno N. Determination of the action spectrum for UV‑induced plasminogen activator synthesis in mouse keratinocytes in vitro. J Dermatol Sci. 1992;4(1):11‑7.
Kim MS, Bang SH, Kim JH, Shin HJ, Choi JH, Chang SE. Tranexamic acid diminishes laser‑induced melanogenesis. Ann Dermatol. 2015;27(3):250‑6.
Karn D, Kc S, Amatya A, Razouria EA, Timalsina M. Oral tranexamic acid for the treatment of melasma. Kathmandu Univ Med J. 2012;10(40):40‑3.
Wu S, Shi H, Wu H, Yan S, Guo J, Sun Y, et al. Treatment of melisma with oral administration of tranexamic acid. Aesthetic Plast Surg. 2012;36(4):964‑70.
Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, Kim MY, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: A preliminary clinical trial. Dermatol Surg. 2006;32(5):626‑31.
Starner RJ, McClelland L, Abdel‑Malek Z, Fricke A, Scott G. PGE(2) is a UVR‑inducible autocrine factor for human melanocytes that stimulates tyrosinase activation. Exp Dermatol. 2010;19(7):682‑4.
Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. J Dermatol Sci. 2007;46(2):111‑6.
17.Sonthalia S. Etiopathogenesis of melasma. In: Sarkar R, editor. Melasma: A Monograph. New Delhi: Jaypee; 2015. p. 6‑14.
Horiuchi T, Hide M, Yamashita K,Ohsawa I. The use of tranexamic acid for on‐demand andprophylactic treatment of hereditary angioedema—Asystematic review. J Cutan Immunol Allergy. 2018;00:1–13.
Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176: 104742.
Grant AL, Letson HL, Morris JL, McEwen P, Hazratwala K, Wilkinson M, et al. Tranexamic acid is associated with selective increase in inflammatory markers following total knee arthroplasty (TKA): A pilot study. J Orthop Surg Res. 2018;13:149.
Chan KH, Farouji I, Slim J, Shaaban HS, Guron G. Tranexamic acid: A potential treatment option for coronavirus disease 2019.J Global Infect Dis. 2020;12(3):160-161.
Barker AB, Wagener BM. An ounce of prevention may prevent hospitalization. Physiol Rev. 2020;100:1347–1348.
Levin MD, Betjes MG, Kwast TH, Wenberg BL, Leebeek FW. Acute renal cortex necrosis caused by arterial thrombosis during treatment for acute promyelocytic leukemia. Haematologica. 2003;88(6):201-7.
Naeye RL. Thrombotic state after a hemorrhagic diathesis, a possible complication of therapy with epsilon-aminocapproic acid. Blood.1962;19:694–701.
